Skip to main content
Imaging Biometrics Limited logo

Imaging Biometrics Limited — Investor Relations & Filings

Ticker · IBT ISIN · JE00BD4H0R42 LEI · 213800SPW48XRJS2QH57 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 23 across all filing types
Latest filing 2025-10-03 Regulatory Filings
Country JE Jersey
Listing IL IBT

About Imaging Biometrics Limited

https://www.imagingbiometrics.com/

Imaging Biometrics Limited is a medical technology company specializing in the development of automated software solutions for advanced medical imaging analysis. The company's primary focus is on neuro-oncology, providing clinicians and researchers with tools to more accurately characterize and monitor brain tumors. Its product portfolio features proprietary and quantitative technologies, such as Delta T1 (dT1) and relative Cerebral Blood Volume (rCBV) mapping, which are designed to extract more meaningful information from MRI scans. These intuitive software solutions integrate into existing clinical workflows to assist with diagnosis, surgical planning, and the assessment of treatment response, aiming to enhance decision-making and improve patient care.

Recent filings

Filing Released Lang Actions
Vivan Therapeutics and IB Announce Partnership
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) announcing a strategic partnership between Imaging Biometrics Limited and Vivan Therapeutics. It details the nature of the collaboration, the companies involved, and contact information. Since it is a general corporate announcement regarding business operations and partnerships that does not fit into specific categories like M&A (which usually implies a takeover or merger of entities) or financial reporting, it is classified as a general regulatory filing.
2025-10-03 English
IB Enters Agreement with MedImageMetric
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a commercial agreement between Imaging Biometrics Limited and MedImageMetric to commercialize a specific software technology. It does not fit into specific categories like financial reports, board changes, or dividend announcements, and serves as a general corporate announcement regarding business operations and partnerships. Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-16 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Yearly Report for the Period Ended 30 June 2025' and contains comprehensive financial statements, including a Consolidated Income Statement, Consolidated Statement of Comprehensive Income, Consolidated Balance Sheet, and Consolidated Statement of Changes in Equity. It provides detailed financial data and management commentary for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-13 English
Grant of Share Options
Remuneration Information Classification · 99% confidence The document is an RNS announcement regarding the 'Grant of Share Options' to key personnel. It details the number of options, exercise prices, and vesting schedules. While it involves share-related activity, it does not represent a new share issue or capital change (SHA) or a transaction in own shares (POS), but rather an internal compensation/incentive arrangement. As it does not fit into the specific categories for director dealings (which are for board members, whereas this specifies 'non-Board IB staff') or other specific categories, it is best classified as a general regulatory filing (RNS).
2025-08-07 English
IB Announces Soft Close to Phase 1 Trial
Regulatory Filings Classification · 99% confidence The document is identified by the 'RNS Number : 8287R' header and concludes with information about RNS, the news service of the London Stock Exchange, which strongly suggests it is a regulatory announcement. The content announces a 'soft close to Phase 1 Trial' for a drug, which is a material operational update regarding clinical development. This type of announcement—a specific, material operational update that is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA)—fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a Capital/Financing Update (CAP) if the focus was purely on funding, but here the focus is on the trial status. Given the structure (short announcement, RNS header, operational news) and the lack of a more specific category (it's not a dividend, director dealing, or M&A), RNS is the most appropriate fallback classification for a general regulatory news service release.
2025-07-21 English
Director/PDMR Dealing
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by a Non-Executive Director (Michael Schmainda) of Imaging Biometrics Limited. It explicitly references 'PDMR dealing' (Persons Discharging Managerial Responsibilities) and provides the required disclosure details under the Market Abuse Regulation, such as the nature of the transaction (purchase), price, volume, and date. This fits the definition of a Director's Dealing report.
2025-07-09 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.